These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 28648954)

  • 1. Fosphenytoin-induced purple glove syndrome: A case report.
    Newman JW; Blunck JR; Fields RK; Croom JE
    Clin Neurol Neurosurg; 2017 Sep; 160():50-53. PubMed ID: 28648954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Purple Glove Syndrome after Phenytoin or Fosphenytoin Administration: Review of Reported Cases and Recommendations for Prevention.
    Garbovsky LA; Drumheller BC; Perrone J
    J Med Toxicol; 2015 Dec; 11(4):445-59. PubMed ID: 26135797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety and efficacy of fosphenytoin for the treatment of status epilepticus.
    Popławska M; Borowicz KK; Czuczwar SJ
    Expert Rev Neurother; 2015; 15(9):983-92. PubMed ID: 26289487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and clinical consequence of the purple glove syndrome in patients receiving intravenous phenytoin.
    O'Brien TJ; Cascino GD; So EL; Hanna DR
    Neurology; 1998 Oct; 51(4):1034-9. PubMed ID: 9781525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective study of the incidence of the purple glove syndrome.
    Burneo JG; Anandan JV; Barkley GL
    Epilepsia; 2001 Sep; 42(9):1156-9. PubMed ID: 11580764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Purple glove syndrome following intravenous phenytoin administration.
    Chokshi R; Openshaw J; Mehta NN; Mohler E
    Vasc Med; 2007 Feb; 12(1):29-31. PubMed ID: 17451091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-minimization analysis of phenytoin and fosphenytoin in the emergency department.
    Touchette DR; Rhoney DH
    Pharmacotherapy; 2000 Aug; 20(8):908-16. PubMed ID: 10939551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical experience with fosphenytoin in adults: pharmacokinetics, safety, and efficacy.
    Knapp LE; Kugler AR
    J Child Neurol; 1998 Oct; 13 Suppl 1():S15-8; discussion S30-2. PubMed ID: 9796747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Purple glove syndrome caused by oral administration of phenytoin.
    Yoshikawa H; Abe T; Oda Y
    J Child Neurol; 2000 Nov; 15(11):762. PubMed ID: 11108512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized evaluation of adverse events and length-of-stay with routine emergency department use of phenytoin or fosphenytoin.
    Coplin WM; Rhoney DH; Rebuck JA; Clements EA; Cochran MS; O'Neil BJ
    Neurol Res; 2002 Dec; 24(8):842-8. PubMed ID: 12500711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intramuscular use of fosphenytoin: an overview.
    Uthman BM; Wilder BJ; Ramsay RE
    Neurology; 1996 Jun; 46(6 Suppl 1):S24-8. PubMed ID: 8649611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Purple glove syndrome].
    Burneo de las Casas J; Barkley G
    Rev Neurol; 2000 Aug 16-31; 31(4):400. PubMed ID: 11008301
    [No Abstract]   [Full Text] [Related]  

  • 13. Phenytoin-Induced Purple Glove Syndrome: A Case Report and Review of the Literature.
    Okogbaa JI; Onor IO; Arije OA; Harris MB; Lillis RA
    Hosp Pharm; 2015 May; 50(5):391-5. PubMed ID: 26405326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Purple glove syndrome occurring after oral administration of phenytoin in therapeutic doses: mechanism still a dilemma.
    Jain RS; Nagpal K; Kumar S; Prakash S; Handa R
    Am J Emerg Med; 2015 Jan; 33(1):123.e5-6. PubMed ID: 25064142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperphosphatemia due to fosphenytoin in a pediatric ESRD patient.
    McBryde KD; Wilcox J; Kher KK
    Pediatr Nephrol; 2005 Aug; 20(8):1182-5. PubMed ID: 15965770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Pharmacokinetic Analysis of Phenytoin After Intravenous Administration of Fosphenytoin in Adult and Elderly Epileptic Patients.
    Higuchi K; Yamashita D; Kashihara Y; Kakara M; Hirota T; Hirakawa M; Ieiri I
    Ther Drug Monit; 2019 Oct; 41(5):674-680. PubMed ID: 31095070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous administration of fosphenytoin: options for the management of seizures.
    Ramsay RE; DeToledo J
    Neurology; 1996 Jun; 46(6 Suppl 1):S17-9. PubMed ID: 8649609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerance of multiple doses of intramuscular fosphenytoin substituted for oral phenytoin in epilepsy or neurosurgery.
    Wilder BJ; Campbell K; Ramsay RE; Garnett WR; Pellock JM; Henkin SA; Kugler AR
    Arch Neurol; 1996 Aug; 53(8):764-8. PubMed ID: 8759983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety, tolerability, and pharmacokinetics of fosphenytoin after intramuscular and intravenous administration in neurosurgery patients.
    Boucher BA; Feler CA; Dean JC; Michie DD; Tipton BK; Smith KR; Kramer RE; Young B; Parks BR; Kugler AR
    Pharmacotherapy; 1996; 16(4):638-45. PubMed ID: 8840370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time-Dependent Decline in Serum Phenytoin Concentration With Heightened Convulsive Seizure Risk by Prolonged Administration of Fosphenytoin in Japanese: A Retrospective Study.
    Ohno Y; Niwa T; Hirai K; Suzuki K; Yamada Y; Hayashi Y; Hayashi H; Suzuki A; Itoh Y
    Ther Drug Monit; 2018 Aug; 40(4):507-511. PubMed ID: 29683874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.